From: Current trials for frontline therapy of mantle cell lymphoma
Leading institution | PI last name | Regimen | Study ID/NCT | EE | Phase | Line | Recruitment | First received | Study results | Cytogenetical inclusion criteria | Age group (years) |
---|---|---|---|---|---|---|---|---|---|---|---|
IHBDH | Yi | R-EDOCH/R-DHAP → HDT/ASCR or R-EDOCH/R-DHAP → MR or MTp | IIT2015007-EC-1 BDH-MCL01 NCT02858804 | 55 | IV | 1st | Recruiting | 7/17/2016 | NA | Not specified | 18–65 |
WUSM | Kahl | BR/RAC | 201603149 NCT02728531 | 15 | I | 1st | Recruiting | 03/30/2016 | NA | t(11;14) and/or CCND1 overex | 18–65 |
MDACC | Wang | RI → Hyper-CVAD | WINDOW I NCT02427620 | 100 | II | 1st | Recruiting | 4/15/2015 | Preliminary [46] CRR 100% mOS and mPFS NR | Blastoid or pleomorphic or, Ki-67 ≥ 30% or mutation TP53, c-MYC or NOTCH | 18–65 |
RPCI | Hernandez-Ilizaliturri | O-HyperCVAD/O-MA | I 201611 NCT01527149 | 37 | II | 1st | Recruiting | 12/12/2011 | NA | t(11;14) and/or CCND1 overex and/or bcl-1/IgH rearragement | 18–70 |
MSKCC | Zelenetz | R-CHOP14 → R-HIDAC → RIT → HDT → ASCR | 11-095 NCT01484093 | 96 | I and II | 1st | Active, not rec | 11/29/2011 | NA | CCND1 or D2 or D3 positive | 18–70 |